Topiramate for the treatment of juvenile myoclonic epilepsy

Detalhes bibliográficos
Autor(a) principal: Sousa,Patrícia da Silva
Data de Publicação: 2005
Outros Autores: Araújo Filho,Gerardo Maria de, Garzon,Eliana, Sakamoto,Américo C., Yacubian,Elza Márcia T.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos de neuro-psiquiatria (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000500001
Resumo: OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of topiramate (TPM) in juvenile myoclonic epilepsy (JME). METHOD: We assessed seizure control and adverse effects of TPM in 22 patients (18 females) aged 13 to 53 years. Target TPM dosage was up to 200 mg/day. The patients were subdivided into 3 groups: those treated with seizure control plus side effects (n=4); treated with non-controlled seizures (n=15) and with JME newly diagnosed (n=3). RESULTS: Sixteen patients completed the first year of the follow-up. Generalized tonic-clonic seizures were completely controlled in 10 (62.5%); more than 50% of reduction in 4 (25.0%) and less than 50% in 2 (12.5%). Myoclonia were controlled in 11 (68.8%) and persisted in 5 (31.2%) patients. Absence seizures were present in 5 (22.7%) of whom 2 (9.0%) showed more than 50% of seizure reduction while 3 (13.6%) presented worsening. Discontinuations were due to inadequate seizure control and adverse events (N=4), low compliance and loss of follow-up (N=2) and subject choice (N=1). CONCLUSION: TPM showed to be an effective and well-tolerated drug in the treatment of JME. Although frequently observed, TPM side effects were tolerable and the drug could be maintained in the majority of patients.
id ABNEURO-1_c041a87609952b00b434ba6fa05f9281
oai_identifier_str oai:scielo:S0004-282X2005000500001
network_acronym_str ABNEURO-1
network_name_str Arquivos de neuro-psiquiatria (Online)
repository_id_str
spelling Topiramate for the treatment of juvenile myoclonic epilepsytopiramatetreatmentjuvenile myoclonic epilepsyOBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of topiramate (TPM) in juvenile myoclonic epilepsy (JME). METHOD: We assessed seizure control and adverse effects of TPM in 22 patients (18 females) aged 13 to 53 years. Target TPM dosage was up to 200 mg/day. The patients were subdivided into 3 groups: those treated with seizure control plus side effects (n=4); treated with non-controlled seizures (n=15) and with JME newly diagnosed (n=3). RESULTS: Sixteen patients completed the first year of the follow-up. Generalized tonic-clonic seizures were completely controlled in 10 (62.5%); more than 50% of reduction in 4 (25.0%) and less than 50% in 2 (12.5%). Myoclonia were controlled in 11 (68.8%) and persisted in 5 (31.2%) patients. Absence seizures were present in 5 (22.7%) of whom 2 (9.0%) showed more than 50% of seizure reduction while 3 (13.6%) presented worsening. Discontinuations were due to inadequate seizure control and adverse events (N=4), low compliance and loss of follow-up (N=2) and subject choice (N=1). CONCLUSION: TPM showed to be an effective and well-tolerated drug in the treatment of JME. Although frequently observed, TPM side effects were tolerable and the drug could be maintained in the majority of patients.Academia Brasileira de Neurologia - ABNEURO2005-09-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000500001Arquivos de Neuro-Psiquiatria v.63 n.3b 2005reponame:Arquivos de neuro-psiquiatria (Online)instname:Academia Brasileira de Neurologiainstacron:ABNEURO10.1590/S0004-282X2005000500001info:eu-repo/semantics/openAccessSousa,Patrícia da SilvaAraújo Filho,Gerardo Maria deGarzon,ElianaSakamoto,Américo C.Yacubian,Elza Márcia T.eng2006-03-02T00:00:00Zoai:scielo:S0004-282X2005000500001Revistahttp://www.scielo.br/anphttps://old.scielo.br/oai/scielo-oai.php||revista.arquivos@abneuro.org1678-42270004-282Xopendoar:2006-03-02T00:00Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologiafalse
dc.title.none.fl_str_mv Topiramate for the treatment of juvenile myoclonic epilepsy
title Topiramate for the treatment of juvenile myoclonic epilepsy
spellingShingle Topiramate for the treatment of juvenile myoclonic epilepsy
Sousa,Patrícia da Silva
topiramate
treatment
juvenile myoclonic epilepsy
title_short Topiramate for the treatment of juvenile myoclonic epilepsy
title_full Topiramate for the treatment of juvenile myoclonic epilepsy
title_fullStr Topiramate for the treatment of juvenile myoclonic epilepsy
title_full_unstemmed Topiramate for the treatment of juvenile myoclonic epilepsy
title_sort Topiramate for the treatment of juvenile myoclonic epilepsy
author Sousa,Patrícia da Silva
author_facet Sousa,Patrícia da Silva
Araújo Filho,Gerardo Maria de
Garzon,Eliana
Sakamoto,Américo C.
Yacubian,Elza Márcia T.
author_role author
author2 Araújo Filho,Gerardo Maria de
Garzon,Eliana
Sakamoto,Américo C.
Yacubian,Elza Márcia T.
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Sousa,Patrícia da Silva
Araújo Filho,Gerardo Maria de
Garzon,Eliana
Sakamoto,Américo C.
Yacubian,Elza Márcia T.
dc.subject.por.fl_str_mv topiramate
treatment
juvenile myoclonic epilepsy
topic topiramate
treatment
juvenile myoclonic epilepsy
description OBJECTIVE: The aim of this study was to evaluate the efficacy and tolerability of topiramate (TPM) in juvenile myoclonic epilepsy (JME). METHOD: We assessed seizure control and adverse effects of TPM in 22 patients (18 females) aged 13 to 53 years. Target TPM dosage was up to 200 mg/day. The patients were subdivided into 3 groups: those treated with seizure control plus side effects (n=4); treated with non-controlled seizures (n=15) and with JME newly diagnosed (n=3). RESULTS: Sixteen patients completed the first year of the follow-up. Generalized tonic-clonic seizures were completely controlled in 10 (62.5%); more than 50% of reduction in 4 (25.0%) and less than 50% in 2 (12.5%). Myoclonia were controlled in 11 (68.8%) and persisted in 5 (31.2%) patients. Absence seizures were present in 5 (22.7%) of whom 2 (9.0%) showed more than 50% of seizure reduction while 3 (13.6%) presented worsening. Discontinuations were due to inadequate seizure control and adverse events (N=4), low compliance and loss of follow-up (N=2) and subject choice (N=1). CONCLUSION: TPM showed to be an effective and well-tolerated drug in the treatment of JME. Although frequently observed, TPM side effects were tolerable and the drug could be maintained in the majority of patients.
publishDate 2005
dc.date.none.fl_str_mv 2005-09-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000500001
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2005000500001
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-282X2005000500001
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
publisher.none.fl_str_mv Academia Brasileira de Neurologia - ABNEURO
dc.source.none.fl_str_mv Arquivos de Neuro-Psiquiatria v.63 n.3b 2005
reponame:Arquivos de neuro-psiquiatria (Online)
instname:Academia Brasileira de Neurologia
instacron:ABNEURO
instname_str Academia Brasileira de Neurologia
instacron_str ABNEURO
institution ABNEURO
reponame_str Arquivos de neuro-psiquiatria (Online)
collection Arquivos de neuro-psiquiatria (Online)
repository.name.fl_str_mv Arquivos de neuro-psiquiatria (Online) - Academia Brasileira de Neurologia
repository.mail.fl_str_mv ||revista.arquivos@abneuro.org
_version_ 1754212758811836416